OSTX:NYE-OS Therapies Incorporated (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.715

Change

+0.06 (+2.18)%

Market Cap

USD 0.07B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.49 (-0.96%)

USD 5.14B
RCUS Arcus Biosciences Inc

-0.41 (-2.50%)

USD 1.58B
NUVB Nuvation Bio Inc

-0.02 (-0.85%)

USD 0.79B
DNA Ginkgo Bioworks Holdings

-0.17 (-2.12%)

USD 0.50B
ANRO Alto Neuroscience, Inc.

+0.02 (+0.50%)

USD 0.37B
ADCT ADC Therapeutics SA

-0.06 (-1.99%)

USD 0.29B
CYBN Cybin Inc

-0.59 (-5.62%)

USD 0.23B
ANVS Annovis Bio Inc

-0.20 (-2.05%)

USD 0.13B
ARMP Armata Pharmaceuticals Inc

-0.01 (-0.27%)

USD 0.08B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B

ETFs Containing OSTX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 64% D 24% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.